BioCentury
ARTICLE | Company News

AmpliPhi BioSciences, Special Phage deal

September 17, 2012 7:00 AM UTC

AmpliPhi will acquire Special Phage in a stock deal under which AmpliPhi has offered up to 40 million shares to Special Phage. The shares are valued at up to $4.4 million based on AmpliPhi's Sept. 7 close of $0.11. After the deal, Special Phage will have up to a 47% stake in AmpliPhi. Anthony Smithyman, Special Phage's founder and managing director, and Tony Gellert, its financial adviser, will join AmpliPhi's board. AmpliPhi's President and CEO Phil Young will lead the combined company alongside AmpliPhi's Chairman Jeremy Curnock-Cook and board members Caroline Williams, Mike Perry and Louis Drapeau. ...